Essential Pharma has acquired Haldol® a first-generation “typical” antipsychotic for the treatment of schizophrenia and other psychiatric conditions

HALDOL® is a first-generation ‘typical’ antipsychotic for the treatment of schizophrenia and some other psychiatric conditions such as schizoaffective disorder and moderate to severe manic episodes associated with bipolar I disorder.  This medicine is included in the World Health Organization’s List of Essential Medicines.

The acquisition is a further significant addition to Essential Pharma’s global portfolio of products in specialty central nervous system (CNS)/neurological medicine and underlines the group’s commitment to ensuring the sustained supply of essential medicines to patients